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Editorial
Treatment of ST-elevation Myocardial Infarction: Need for a Better
Reperfusion Strategy
CHU-PAK LAU, WAI-HONG CHEN, PUI-YIN LEE
From Division of Cardiology, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong
The traditional definition of acute myocardial
infarction (MI) is changing, largely because of the
emergence of newer markers of myocardial damage.
Using the conventional indicators of twice creatinine
kinase rise, MI are now categorised as ST-elevation MI
(Q wave MI) and non-ST elevation MI (non-Q MI). A
recent chart review in Queen Mary Hospital shows that
patients with ST-elevation MI were younger, mostly
males, and had a higher in-hospital mortality than nonST elevation MI (Table 1). Whilst a debate on the best
management strategy for non-ST elevation MI remains,
there are recent evidence and on-going trials on
improving the treatment of ST-elevation MI, which still
carries an in-hospital mortality of 6-8% in randomised
trials, and up to 20% in "real" life cases in the United
States.
Reperfusion therapy using fibrinolytic agents is
the standard of care in the management of patients
presenting with ST-elevation MI. The goal of
reperfusion therapy is rapid, complete, and sustained
restoration of normal flow in the infarct-related artery
(IRA), thereby preserving left ventricular function and
reducing mortality. Recent evidence have shown that
re-establishment of normal epicardial flow does not
mean successful myocardial reperfusion. 1 Despite
attaining Thrombolysis in Myocardial Infarction (TIMI)
grade 3 flow in the IRA, myocardial reperfusion may
still be impaired after primary percutaneous
transluminal coronary angioplasty (PTCA). This is
associated with large infarcts, poor left ventricular
functional recovery, and increased mortality.2-6 Two
methods have been developed recently to characterise
myocardial reperfusion. The TIMI myocardial perfusion
grade uses the clearance of the myocardial blush on the
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coronary angiogram to define different grades of
myocardial reperfusion.7 This angiographic method of
assessing myocardial reperfusion involves the
performance of an invasive procedure and is not readily
available. Resolution of ST elevation on the surface
electrocardiogam (EKG) has been shown to correlate
closely with myocardial contrast echocardiography
findings8 and thus is a marker of myocardial reperfusion.
Moreover, ST resolution carries prognostic implications
in patients with acute MI receiving fibrinolytic agents
or undergoing primary PTCA.9-16
Although new fibrinolytic agents have been
developed and are starting to replace tissue plasminogen
activator in the Western world, streptokinase is still used
in many parts of the world as the fibrinolytic of first
choice in ST-elevation MI. Using ST segment resolution
as an endpoint for successful reperfusion strategy, a
recent local study (Chen WH et al, unpublished
observation) suggests that stroptokinese resulted in
complete ST resolution in only one-quarter of patients
with ST-elevation MI. This strategy compared poorly
to a third-generation fibrinolytic, lanoteplase, which

Table 1. Clinical characteristics and outcome of STelevation and non-ST elevation MI in Queen Mary
Hospital in 1998 - 1999

Age (yrs)
% Female
Risk Factor
Smoking
Hypertension
Diabetes
Hypercholesterolaemia

ST-elevation
MI
n=200
65 ± 12
20%

Non-ST
elevation MI
n=100
73 ± 11
41%

50%
32%
22%
18%

53%
40%
26%
20%

In-hospital mortality

16%

11%
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resulted in ST resolution of 33% in 60 minutes.17 The
better survival of patients treated with "front-loaded"
tissue plasminogen activator and heparin, over
streptokinase in patients with large arterior MI with
early presentation was well documented in the GUSTOI trial.18
However, with the present fibrinolytic therapy,
full myocardial reperfusion is only achieved in 30-45%
of patients,19 and reocclusion occurs in about 30% by
three months, which is associated with increased
mortality. Resistance to thrombolysis results from the
highly complex constituents of the clot that obstructs
the IRA: a mixture of activated platelets, fibrin and
thrombin. Thus fibrinolytics that act on the fibrin portion
of the clot result in incomplete lysis. Worse still,
exposure of clot-bound thrombin can cleave fibrinogen
to fibrin, thus promoting re-thrombosis. In addition,
platelet factors that result in vasoconstriction also limit
recanalisation of IRA.
Thus to optimise myocardial reperfusion, two
additional strategies may be considered in addition to
fibrirolytics: anti-platelet and anti-thrombin therapy.
Anti-thrombin therapy is already an integral element in
current fibrinolytic treatment, especially with the tissue
plasminogen activators. It is attractive to consider the
low molecular weight heparins, with their more
predictable bioavailability and factor Xa inhibition,
which may be advantageously combined with these
plasmogen activators. 20 The glycoprotein IIbIIIa

inhibitors, which blocks the final common pathway of
platelet activation,20 has also been tested in pilot studies
in combination with fibrinolytics in addition to aspirin.
Early results suggest that these combinations may result
in a higher percent of TIMI-3 flow than with
conventional fibrinolytics. With proper dose reduction
of fibrinolytic, the excessive bleeding risk may be
acceptable. 21 Whether these newer "cocktails" are
translated into clinical benefits must await the results
of currently ongoing large scale trials.
While fascinated by the newer chemical clot
busters, one must not forget the more direct and proven
approach: primary PTCA. Unfortunately at present,
none of the Hospital Authority hospitals are equipped,
both in equipment and personnel, to perform primary
PTCA on a routine basis. This certainly is an area worth
developing, as Hong Kong is a small area and a high
percentage of patients with MI can reach the hospital
within 4 hours, making PTCA a feasible option. As
nearly half of the patients even with the newer
fibrinolytics do not achieve optimal reperfusion, it is
not unreasonable to adopt a "staged" strategy to perform
rescue PTCA, perhaps using the non-invasive ST
resolution method at 60 minutes as a triage. Finally, a
"hybrid" approach may be considered in which lower
dose lytics are given while getting ready to perform
angioplasty, to optimise myocardial salvation.
A hypothetic scenario of the outcome of patients
admitted to a hospital with MI is shown in the Figure 1.

Figure 1. A hypothetical treatment path of 100 patients with acute MI admitted to a hospital,
and the reasons for not achieving optimal myocardial perfusion therapy.
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Roughly, only one quarter of these patients will derive
optimal myocardial reperfusion. There remains many
areas of improvement, including avoiding late
presentation through public education and reducing the
numbers of patients who are thrombolytic ineligible, in
addition to the above mentioned strategies. Finally one
must never forget that 1 in 4 patients who have a MI
die before reaching hospital, emphasing that we need
to pay attention to primary prevention of coronary risk
factors, and improving our means to identify the plaque
vulnerable to rupture.
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